Liver impairment study for cancer drug tazemetostat halted early

NCT ID NCT04241835

Terminated Knowledge-focused Sponsor: Epizyme, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how the cancer drug tazemetostat is processed in the body of people with advanced solid tumors who also have moderate or severe liver impairment. Researchers compared drug levels in these patients to those with normal liver function. The trial was terminated early, so only limited information is available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tazemetostat (Tazverik)
What this could lead to: If successful, this could help doctors understand how to safely dose tazemetostat in cancer patients with liver problems.
What could go wrong: This was a very small, early-phase study that was terminated, so we may never get clear answers. It only looked at drug levels, not whether the drug works against cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid system neoplasm liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT SOLID TUMOR HEPATIC IMPAIRMENT

Contacts and locations

Locations

Antwerp University Hospital

Edegem, Antwerp, 2650, Belgium
Centre Oscar Lambret

Lille, 59020, France
Comprehensive Cancer Center of Nevada

Las Vegas, Nevada, 89014, United States
Florida Cancer Specialists & Research Institute

Lake Mary, Florida, 32746, United States
Gabrail Cancer Center

Canton, Ohio, 44718, United States
Hematology Oncology Consultants

Royal Oak, Michigan, 48073, United States
Institut Bergonie

Bordeaux, 33076, France
Institut de Cancérologie Strasbourg Europe

Strasbourg, France
Mary Crowley Cancer Research

Dallas, Texas, 75230, United States
MedPolonia

Poznan, Greater Poland Voivodeship, 60693, Poland
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Chicago, Illinois, 60611, United States
Rutgers Cancer Institute

New Brunswick, New Jersey, 08901, United States
Summit Clinical Research, s.r.o

Bratislava, 831 01, Slovakia
Virginia Cancer Specialists

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.